89
Participants
Start Date
January 4, 2022
Primary Completion Date
January 27, 2025
Study Completion Date
January 27, 2025
HMPL-760
HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
Beijing Chao-Yang Hospital, Capital Medical University, Beijing
The First Affiliated Hospital of Xiamen University, Xiameng
Sun Yat-sen University Cancer Center, Guangzhou
Guangxi Medical University cancer Hospital & Guangxi Cancer Institute, Nanning
Affiliated Hospital of Chengde Medical University, Chengde
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Chenzhou First People's Hospital, Chenzhou
First Affiliated Hospital of Soochow University, Suzhou
Jiangxi Cancer Hospital, Nanchang
Jilin Cancer Hospital, Changchun
The Second Affiliated Hospital of Dalian Medical University, Dalian
The First Hospital of China Medical University, Shenyang
Harbin Medical University Cancer Hospital, Harbin
Qilu Hospital of Shandong University, Jinan
Heping Hospital Affiliated to Changzhi Medical College, Changzhi
Shanxi Bethune Hospital, Taiyuan
West China Hospital of Sichuan University, Chengdu
Affiliated Hangzhou First People's Hospital ,Zhejiang University School of Medicine, Hangzhou
Chongqing university cancer hospital, Chongqing
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Lead Sponsor
Hutchmed
INDUSTRY